According to a recent market survey by Future Market Insights (FMI), the global axillary hyperhidrosis treatment market was valued at USD 1.6 billion in 2022. The market is anticipated to experience significant growth, with projections estimating it will reach USD 3.3 billion by 2033.
Axillary hyperhidrosis, characterized by excessive underarm sweating, can severely impact the quality of life. The anticipated market growth underscores the importance of innovative treatments that offer patients relief from this often debilitating condition.
With continuous research and development, the market is expected to see the introduction of more advanced and accessible treatment options, further driving its expansion over the next decade.
As more people become aware of Axillary Hyperhidrosis, more people are being diagnosed and seeking treatment, causing the market for Axillary Hyperhidrosis Treatment to develop. Technological advancements have resulted in the creation of new and creative treatment alternatives, such as minimally invasive procedures and non-invasive technologies, which are propelling the Axillary Hyperhidrosis Treatment market forward.
Excessive underarm perspiration can cause humiliation and social stigma, hence many people with Axillary Hyperhidrosis seek treatment for cosmetic reasons. This is increasing the need for Axillary Hyperhidrosis aesthetic therapies. Combination therapies, which employ numerous therapy modalities to treat Axillary Hyperhidrosis, are gaining popularity among patients and healthcare practitioners alike. This is propelling the market for Axillary Hyperhidrosis Treatment Combination Therapies forward.
Overall, these factors are driving demand for effective and new treatment options in the Axillary Hyperhidrosis Treatment market and are projected to continue to do so in the coming years.
Axillary Hyperhidrosis Treatment Market Key Takeaways:
Drug therapy is the leading segment of treatment among patients and professionals, and held about 62.7% market share in 2022, due to its non-invasive nature and high efficacy in reducing excessive sweating in patients.
- By distribution channel, the retail pharmacies dominated the global Axillary Hyperhidrosis Treatment market withholding the total market share of about 34.2% by the end of 2022, owing to the convenience and ease of accessibility to a range of products from OTC/off-label products to licensed products.
- By region, North America is leading in the global Axillary Hyperhidrosis Treatment market and is expected to continue to do so with a projected CAGR rate of 5.4% during the forecasted years.
“Increasing adoption of combination therapies and growing awareness and diagnosis of the condition to create the lucrative potential for the market to grow,” says an analyst at Future Market Insights (FMI).
Axillary Hyperhidrosis Treatment Market Competition:
Key participants in the market for Axillary Hyperhidrosis Treatment employ expansion of the company through acquisitions, mergers, collaborations, and partnerships. Key players are concentrating on strategies like expanding sales and implementing new technology for the creation of novel products.
- In December 2021, Sientra, Inc. announced that it had entered into an agreement to acquire all of the assets related to the novel fat grafting technology from AuraGen Aesthetic, LLC.
- In August 2022, GSK plc announced that it had acquired Affinivax, Inc (Affinivax), a clinical-stage biopharmaceutical company based in Cambridge, Boston, Massachusetts.
Axillary Hyperhidrosis Treatment Market Key Players:
- Allergan plc. (AbbVie)
- Journey Medical Corporation (Dermira, Inc.)
- Riemann A/S (Orkla)
- SweatBlock
- Certain Dri
- miraDry, Inc. (Sientra)
- STRATUS PHARMACEUTICALS INC.
- Duradry
- Persn & Covey
- GlaxoSmithKline Plc.
- Carpe
- SweatStop® International
- CORAD Healthcare
- ZeroSweat
A Old Full Report Analysis Click Here
Axillary Hyperhidrosis Treatment Market Key Segments Covered:
By Treatment:
- Drug Therapy
- Antiperspirants (Both OTC & Rx)
- Antiperspirants Spray
- Antiperspirants Roll-On
- Antiperspirants Wipes
- Antiperspirants Lotion & Gel
- Antihypertensive Drugs
- Anticholinergic Agents
- Alpha-Adrenergic Agonists
- Antiperspirants (Both OTC & Rx)
- Botulinum Toxins
- Medicated Wipes
- Microwave Therapy
By Distribution Channel:
- Hospitals
- General Physician’s Clinics
- Retail Pharmacy Chains
- Drug Stores
- Online Sales
- Manufacturer websites
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube